ONX 0801 (trisodium)

• UNSPSC Description:

  ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors[1][2].

• Target Antigen:

  Thymidylate Synthase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/onx-0801-trisodium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@H](C(O[Na])=O)CCC(N[C@@H](C(O[Na])=O)CCC(O[Na])=O)=O)C1=CC=C(N([C@H]2CCC3=C2C=C4C(NC(CO)=NC4=O)=C3)CC#C)C=C1

• Molecular Weight:

  713.58

• References & Citations:

  [1]Anna Tochowicz, et al. Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem. 2013 Jul 11;56(13):5446-55.|[2]David D Gibbs, et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005 Dec 15;65(24):11721-8.|[3]Chau Ng, et al. Efficacy and tolerability of the thymidylate synthase (TS) inhibitor, BGC 945 is mediated through its selective uptake via the α-folate receptor (α-FR) in IGROV-1 human tumor xenografts. AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 1

• CAS Number:

  1097638-00-0